Text Size: A A A      Contrast:       
 

Novartis MERLIN Study - Wet AMD

Study of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections (MERLIN)

Study Description:

Condition or Disease

Intervention / Treatment

Phase

Sponsor

Status

Neovascular  "Wet" Age-Related Macular Degeneration

Brolucizumab

Phase 3

Novartis

Enrolling

Detailed Description:

The purpose of this study is to compare safety and efficacy of brolucizumab 6 mg dosed every 4 weeks to aflibercept 2 mg dosed every 4 weeks in those nAMD patients with retinal fluid despite frequent anti-Vascular Endothelial Growth Factor (VEGF) injections.

Inclusion Criteria:

  • Age 50 years or older.
  • Sign informed consent.
  • Diagnosis of wet age-related macular degeneration (AMD).
  • Currently receiving anti-VEGF injections.

Exclusion Criteria:

  • Active infection or inflammation in either eye.
  • Significant fibrosis in the study eye.
  • Recent ocular surgery.
  • Uncontrolled glaucoma.
  • Previous treatment with brolucizumab in the study eye.
  • Use of medications as specified in the protocol.
  • Pregnant, nursing.
  • Of child-bearing potential unless using highly effective method of contraception.
    Other protocol-defined inclusion/exclusion criteria may apply.

Contact:

Beachwood Office – Dianne Himmelman 216-831-5700   •   dhimmelman@retina-assoc.com.

To learn more: 

https://clinicaltrials.gov/ct2/show/NCT03710564